title: Cabozantinib Approved for Renal Cell Carcinoma.
abstract: The FDA has approved cabozantinib, a tyrosine kinase inhibitor, for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy. In a randomized phase III trial, participants who received cabozantinib did better across three efficacy endpoints-progression-free survival, overall survival, and objective response rate-than those given the mTOR inhibitor everolimus.
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C558660:cabozantinib